Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 2/2003

01-03-2003

Building the infrastructure for nationwide cancer surveillance and control – a comparison between The National Program of Cancer Registries (NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States)

Authors: Phyllis A. Wingo, Patricia M. Jamison, Robert A. Hiatt, Hannah K. Weir, Paul M. Gargiullo, Mary Hutton, Nancy C. Lee, H. Irene Hall

Published in: Cancer Causes & Control | Issue 2/2003

Login to get access
Metadata
Title
Building the infrastructure for nationwide cancer surveillance and control – a comparison between The National Program of Cancer Registries (NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States)
Authors
Phyllis A. Wingo
Patricia M. Jamison
Robert A. Hiatt
Hannah K. Weir
Paul M. Gargiullo
Mary Hutton
Nancy C. Lee
H. Irene Hall
Publication date
01-03-2003
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 2/2003
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1023/A:1023002322935

Other articles of this Issue 2/2003

Cancer Causes & Control 2/2003 Go to the issue

OriginalPaper

Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States)

OriginalPaper

Occupation and the risk of adult glioma in the United States

OriginalPaper

Case–control study of lung cancer during 1994–1997 in the birth cohort in Tasmania, Australia, with an excess of female cases during 1983–1992

OriginalPaper

Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States)

OriginalPaper

Breast cancers among very young premenopausal women (United States)

OriginalPaper

Cancer incidence patterns in Koreans in the US and in Kangwha, South Korea
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits